RT Journal Article
SR Electronic
T1 Developing contents for a digital drug adherence tool with reminder cues and personalized feedback: a formative mixed-methods study among children and adolescents living with HIV in Tanzania
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.22.23287383
DO 10.1101/2023.03.22.23287383
A1 Swai, Iraseni
A1 ten Bergen, Lisa Lynn
A1 Mtenga, Alan
A1 Maro, Rehema
A1 Ngowi, Kennedy
A1 Mtesha, Benson
A1 Lekashingo, Naomi
A1 Msosa, Takondwa
A1 Rinke de Wit, Tobias F.
A1 Aarnoutse, Rob
A1 Sumari-de Boer, Marion
YR 2023
UL http://medrxiv.org/content/early/2023/03/27/2023.03.22.23287383.abstract
AB Children and adolescents living with HIV (CALHIV) form a significant proportion of people living with HIV (PLHIV). Optimal adherence (>95%) to medication is needed to achieve viral suppression. However, optimal adherence remains a challenge among CALHIV. Digital adherence tools (DAT) like the Wisepill® device have proven feasible among adult PLHIV. Still, there are concerns about unwanted disclosure of HIV status due to content in short message service (SMS) that serve as reminders. We assessed the needs, contents, and acceptability of a DAT intervention among CALHIV.We conducted a mixed-methods study among CALHIV with their parents/guardians. We performed a survey and then purposively selected participants who used the intervention for one month. They received SMS text reminders that differed over time from asking if the medication was taken to more neutral SMS like “take care”. After one month, participants received tailored feedback based on automatically generated adherence reports. Afterwards, we completed exit interviews, in-depth interviews, and focus-group discussions. We analysed quantitative findings descriptively and used thematic content analysis for qualitative data.We included 284 participants in the survey and 40 used the intervention. Among participants who often forgot medication intakes, 93% of adolescents and 83% of children’s parents/guardians were interested in receiving reminders. Among participants who used DAT, 90% had good experience receiving reminders and agreed that SMS made them take medication. However, 25% experienced network problems. Participants were happy to use the device. Further, they preferred neutral reminder SMSs that did not mention the word ‘medication’, but preserved confidentiality. Adherence reports inspired good adherence. None of the participants experienced unwanted disclosure or stigmatisation due to DAT. However, 5% of adolescents were concerned about being monitored daily.This study provided insights on how to customise DAT. We will implement this in a clinical trial to assess effectiveness in improving adherence.Author’s summary CALHIV are required to take antiretroviral medication on time, every day, for the rest of their lives. That is necessary to suppress the virus and live a healthy life. Maintaining that consistency is not easy. Digital tools that assist in reminding medication time, like the Wisepill device, have proven feasible among adult PLHIV. However, there are concerns about HIV status disclosure due to the contents used in the SMSs. We tested a DAT intervention in which participants used the Wisepill device, received reminder SMS in their phones and adherence reports on how they took medication over a month. We sent SMS contents that differed over time from asking if the medication was taken to more neutral SMS like “take care”. After one month, we asked participants their opinions about the interventions. Most participants were happy to use the device and to receive neutral SMS contents that did not mention ‘medication’ and which preserved their confidentiality. Adherence feedbacks motivated good adherence behaviour. However, some participants experienced network challenges, and 5% of adolescents were concerned about being monitored daily. We will use preferred SMS contents in the clinical trial that will assess the effectiveness of the DAT in improving adherence among CALHIV.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded and supported by the European and Developing Countries Clinical Trials Partnership (EDCTP) under the senior fellowship plus TMA2818.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the College Research and Ethical Review Committee (CRERC) of Kilimanjaro Christian Medical University College (KCMUCo) and the National Health Research Ethics Sub-Committee (NatHREC) of the National Medical Research Institute (NIMR) of Tanzania.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe quantitative and qualitative data used in this study will be made available upon request from the corresponding author.